[go: up one dir, main page]

DE69906944D1 - 20-hete antagonisten und agonisten - Google Patents

20-hete antagonisten und agonisten

Info

Publication number
DE69906944D1
DE69906944D1 DE69906944T DE69906944T DE69906944D1 DE 69906944 D1 DE69906944 D1 DE 69906944D1 DE 69906944 T DE69906944 T DE 69906944T DE 69906944 T DE69906944 T DE 69906944T DE 69906944 D1 DE69906944 D1 DE 69906944D1
Authority
DE
Germany
Prior art keywords
hete
agonists
antagonists
acid
hydroxyeicosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69906944T
Other languages
English (en)
Other versions
DE69906944T2 (de
Inventor
J Roman
R Falck
Magdalena Alonso-Galicia
R Jacobs
R Harder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Medical College of Wisconsin Research Foundation Inc
University of Texas at Austin
Original Assignee
University of Texas System
Medical College of Wisconsin Research Foundation Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Medical College of Wisconsin Research Foundation Inc, University of Texas at Austin filed Critical University of Texas System
Publication of DE69906944D1 publication Critical patent/DE69906944D1/de
Application granted granted Critical
Publication of DE69906944T2 publication Critical patent/DE69906944T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DE69906944T 1998-02-26 1999-02-24 20-hete antagonisten und agonisten Expired - Lifetime DE69906944T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7609198P 1998-02-26 1998-02-26
PCT/US1999/004020 WO1999043310A2 (en) 1998-02-26 1999-02-24 20-hete antagonists and agonists

Publications (2)

Publication Number Publication Date
DE69906944D1 true DE69906944D1 (de) 2003-05-22
DE69906944T2 DE69906944T2 (de) 2003-12-24

Family

ID=22129876

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69906944T Expired - Lifetime DE69906944T2 (de) 1998-02-26 1999-02-24 20-hete antagonisten und agonisten

Country Status (13)

Country Link
US (3) US6395781B1 (de)
EP (1) EP1056449B1 (de)
JP (1) JP3921583B2 (de)
KR (1) KR100390312B1 (de)
CN (1) CN1148179C (de)
AT (1) ATE237321T1 (de)
AU (1) AU750579B2 (de)
CA (1) CA2320706C (de)
DE (1) DE69906944T2 (de)
DK (1) DK1056449T3 (de)
ES (1) ES2194444T3 (de)
PT (1) PT1056449E (de)
WO (1) WO1999043310A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
EP1226819B1 (de) 1999-11-01 2006-01-18 Taisho Pharmaceutical Co., Ltd Hemmer für das 20-hete-produzierende enzym
AU2001288798B2 (en) * 2000-11-03 2006-11-02 Mcw Research Foundation, Inc. Use of 20-HETE synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
US20020151734A1 (en) * 2001-01-02 2002-10-17 Schwartzman Michal Laniado 12-HETrE analogs and methods of use thereof
EP1389611B1 (de) * 2001-04-26 2012-06-27 Taisho Pharmaceutical Co., Ltd Inhibitoren der produktion von 20-hydroxyeicosatetraensäure
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
US6825232B2 (en) 2002-06-14 2004-11-30 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
CN1909896A (zh) * 2003-11-14 2007-02-07 Mcw研究基金会股份有限公司 调节血管生成和癌细胞增殖的方法
US20070004802A1 (en) * 2004-09-16 2007-01-04 Roman Richard J Method for treating renal disease
US20060063836A1 (en) * 2004-09-16 2006-03-23 Roman Richard J Method for treating renal disease
US20080306155A1 (en) * 2004-09-16 2008-12-11 Roman Richard J Method for treating renal disease
WO2007047447A2 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2008034011A2 (en) 2006-09-13 2008-03-20 Mcw Research Foundation, Inc. Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
US20090069418A1 (en) * 2007-04-25 2009-03-12 Alkayed Nabil J Compositions and Methods for the Treatment of Disorders Associated with Aberrant Vasodilation
EP2208720A1 (de) * 2009-01-13 2010-07-21 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Neuartige Eicosanoidderivate
KR102258677B1 (ko) * 2013-12-10 2021-06-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간 질환의 감별 진단
PL3097076T3 (pl) 2014-01-22 2019-10-31 Max Delbrueck Centrum Fuer Molekulare Medizin Nowe pochodne CYP-eikozanoidowe
WO2017156164A1 (en) * 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334736A (en) 1991-05-16 1994-08-02 University Of Texas System Board Of Regents Functionalizing carbohydrate derivatives by base-induced β-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits
US5502226A (en) * 1994-11-14 1996-03-26 Elizabeth Arden Co., Division Of Conopco, Inc. Process of preparing ω-hydroxy acids
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists

Also Published As

Publication number Publication date
JP3921583B2 (ja) 2007-05-30
CN1291890A (zh) 2001-04-18
CA2320706C (en) 2007-05-01
AU2786199A (en) 1999-09-15
DE69906944T2 (de) 2003-12-24
EP1056449B1 (de) 2003-04-16
US20020049244A1 (en) 2002-04-25
ATE237321T1 (de) 2003-05-15
ES2194444T3 (es) 2003-11-16
US20020072534A1 (en) 2002-06-13
US6395781B1 (en) 2002-05-28
EP1056449A2 (de) 2000-12-06
KR100390312B1 (ko) 2003-07-12
US6596769B2 (en) 2003-07-22
US6605641B2 (en) 2003-08-12
KR20010034544A (ko) 2001-04-25
JP2003522098A (ja) 2003-07-22
WO1999043310A3 (en) 1999-10-07
WO1999043310A2 (en) 1999-09-02
AU750579B2 (en) 2002-07-25
PT1056449E (pt) 2003-09-30
CA2320706A1 (en) 1999-09-02
CN1148179C (zh) 2004-05-05
DK1056449T3 (da) 2003-08-11

Similar Documents

Publication Publication Date Title
ATE237321T1 (de) 20-hete antagonisten und agonisten
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
DZ2788A1 (fr) Agonistes et antagonistes selectifs à IL-2.
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
NO994906D0 (no) GnRH antagonister som er modifisert i stillinger 5 og 6
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BG105256A (en) Muscarinic agonists and antagonists
BR9813817A (pt) Análogos de hemiasterlina
RS50165B (sr) Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
ATE28188T1 (de) Antikonvulsive mittel.
ATE57526T1 (de) P-acylaminobenzamide.
RS47804A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
ITTO940212V0 (it) Attrezzatura per compassi sostitutiva dell'ago.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition